MICA and urogenital neoplasm: In addition, it has been reported that administration of a non-blocking monoclonal antibody specific to shed MICA/B along with an anti-CTLA-4 antibody synergistically boosts anti-tumor immune response and alleviates anti-CTLA-4 induced colitis in a genetically engineered model of spontaneous prostate cancer, TRAMP (Transgenic adenocarcinoma of the mouse prostate) when bred onto a MICA transgenic background [20].